Literature DB >> 7850550

Rationale for elective contralateral mastectomy with immediate bilateral reconstruction.

S S Kroll1, M J Miller, M A Schusterman, G P Reece, S E Singletary, F Ames.   

Abstract

BACKGROUND: Women with breast cancer treated by mastectomy with immediate breast reconstruction can get exceptionally good results if the reconstruction is performed with autogenous tissue using the transverse rectus abdominis myocutaneous (TRAM) flap. Bilateral reconstruction with TRAM flaps is also possible, but only if both breasts are reconstructed at the same time. To avoid the possibility of subsequently developing contralateral malignancy and having to undergo assymetrical reconstruction with a different technique, some patients have chosen the alternative of bilateral mastectomy with bilateral immediate reconstruction. This is only reasonable if the incidence of failure in bilateral breast reconstruction is very low.
METHODS: We prospectively studied reconstructive outcomes in 100 patients who had breast cancer and who underwent bilateral mastectomy and reconstruction (using implants as well as TRAM flaps). We also reviewed the histologic findings in 88 prophylactically removed high-risk breasts.
RESULTS: Successful outcomes were initially achieved in 95 patients; of the 5 failures, two were successfully reconstructed with alternative techniques for an overall success rate of 97%. Of the 63 patients reconstructed with bilateral TRAM flaps, all but one (98%) were successful on the first try. TRAM flap reconstructions were significantly more likely to be successful than were those based on implants (p = 0.05). Previously unsuspected invasive cancer was found in 3 patients (3.4%), whereas carcinoma in situ was found in 5 patients (5.7%) and in another 18 patients (20%) cellular atypia was present.
CONCLUSIONS: Bilateral breast reconstruction has a low incidence of failure, particularly if TRAM flaps are used. For selected patients, elective contralateral mastectomy with immediate bilateral reconstruction is a reasonable treatment alternative provided that the necessary expertise is available and the patients clearly understand the risks.

Entities:  

Mesh:

Year:  1994        PMID: 7850550     DOI: 10.1007/bf02303609

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  11 in total

1.  A comparison of outcomes using three different methods of breast reconstruction.

Authors:  S S Kroll; B Baldwin
Journal:  Plast Reconstr Surg       Date:  1992-09       Impact factor: 4.730

2.  BILATERAL PRIMARY BREAST CANCER; A PROSPECTIVE CLINICOPATHOLOGICAL STUDY.

Authors:  G F ROBBINS; J W BERG
Journal:  Cancer       Date:  1964-12       Impact factor: 6.860

3.  Selective, elective, prophylactic contralateral mastectomy.

Authors:  H P Leis
Journal:  Cancer       Date:  1971-10       Impact factor: 6.860

Review 4.  Lobular carcinoma in situ and intraductal carcinoma of the breast.

Authors:  P P Rosen
Journal:  Monogr Pathol       Date:  1984

5.  Risk of familial breast cancer.

Authors:  D E Anderson; M D Badzioch
Journal:  Cancer       Date:  1985-07-15       Impact factor: 6.860

6.  Familial breast cancer in a population-based series.

Authors:  R Ottman; M C Pike; M C King; J T Casagrande; B E Henderson
Journal:  Am J Epidemiol       Date:  1986-01       Impact factor: 4.897

7.  Autogenous tissue reconstruction in the mastectomy patient. A critical review of 300 patients.

Authors:  C R Hartrampf; G K Bennett
Journal:  Ann Surg       Date:  1987-05       Impact factor: 12.969

8.  Multicentricity and bilaterality in invasive breast carcinoma.

Authors:  M L Lesser; P P Rosen; D W Kinne
Journal:  Surgery       Date:  1982-02       Impact factor: 3.982

9.  Patient selection for prophylactic mastectomy: who is at high risk?

Authors:  P K Buehler
Journal:  Plast Reconstr Surg       Date:  1983-09       Impact factor: 4.730

10.  Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol No. 4). XI. Bilateral breast cancer.

Authors:  E R Fisher; B Fisher; R Sass; L Wickerham
Journal:  Cancer       Date:  1984-12-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.